Matthew Turner, President of Patient Affordability, Paysign, touches on how evolving payer tactics appear to be pushing ...
Matthew Turner, President of Patient Affordability, Paysign discusses how next-generation copay assistance appears to be less about consolidating services under one vendor and more about assembling ...
Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.
Excalipoint Therapeutics closed an oversubscribed $68.7 million seed financing, one of the largest early-stage rounds for a Chinese biotechnology company, to advance its pipeline of six T-cell engager ...
In today's Pharmaceutical Executive Daily, a federal judge blocks RFK Jr.'s reconstituted vaccine advisory committee and ...
Vera Pomerantseva, Director of Product Management for RBQM, eClinical Solutions, mentions how eClinical Solutions positioned ...
Manufacturers are rethinking patient assistance program architecture amid the economic pressures of the Inflation Reduction Act.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results